|
See related Neupro transdermal patch information |
|
|
|
Manufacturer |
UCB |
|
Distributor |
Hong Kong: Orient Europharma |
|
Contents |
Rotigotine |
|
Indications |
Treatment of signs & symptoms of idiopathic Parkinson's disease, either w/ or w/o concomitant levodopa therapy. |
|
Dosage |
Apply on skin once daily. Rotate application site daily. Do not apply to the same site more than once every 14 days. Monotherapy Initially a single dose of 2 mg/day, dose increased by 2 mg/24 hr each wk (eg 2 mg/24 hr in wk 1, 4 mg/24 hr in wk 2, 6 mg/24 hr in wk 3 & 8 mg/24 hr in wk 4), until an effective dose is reached. Max: 8 mg/24 hr. Combination w/ levodopa Initially 4 mg/24 hr & increase in increments of 2 mg wkly. Max: 16 mg/24 hr. |
|
Contraindications |
Hypersensitivity. Remove patch prior to MRI or cardioversion to avoid burns. Pregnancy & lactation. |
|
Special Precautions |
Monitor BP. Consider dose reduction or termination of therapy when somnolence or sudden onset of sleep occurs, or when there is persistent, spreading or serious skin rash at the application site. Discontinue treatment in case of generalized skin reaction. Avoid exposure to direct sunlight until the skin is healed. W/draw gradually to avoid symptoms of neuroleptic malignant syndrome. Compulsive behaviours & hallucinations have been reported. Severe hepatic impairment. Avoid driving & operating machinery. |
|
Adverse Drug Reactions |
Somnolence, dizziness, nausea, vomiting, application site reactions. Anorexia, hallucinations, sleep attacks, insomnia, abnormal dreams, headache, dyskinesia, lethargy, orthostatic hypotension, HTN, hiccup, cough, constipation, diarrhoea, dry mouth, dyspepsia, hyperhydrosis, erythema, pruritus, asthenic conditions & peripheral oedema.
View ADR Monitoring Form |
|
Drug Interactions |
Neuroleptics (eg phenothiazine, butyrophenone, thioxanthene) or metoclopramide. Sedatives or other CNS depressants (eg benzodiazepines, antipsychotics, antidepressants) or alcohol.
View more drug interactions with Neupro |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
ATC Classification |
N04BC09 - rotigotine ; Belongs to the class of dopamine agonists. Used in the management of Parkinson's disease. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Neupro transdermal patch |
|
Neupro 2 mg/24 hr x 10 cm2 |
|
Neupro 4 mg/24 hr x 20 cm2 |
|
Neupro 6 mg/24 hr x 30 cm2 |
|
Neupro 8 mg/24 hr x 40 cm2 |
|
|
|
Manufacturer: |
UCB |
|
Distributor: |
Hong Kong: Orient Europharma
|
|
|
|
